论文部分内容阅读
将78例新诊断T2DM患者,随机分为地特胰岛素联合瑞格列奈组和预混人胰岛素(诺和灵30R)组进行治疗,观察治疗前后的FBG、2hBG、HbA1c、C-P、BMI、低血糖发生率、胰岛素用量。结果治疗后,两组患者的FBG、2hBG、HbA1c均较基线显著降低(P<0.05),两组间差异无统计学意义(P>0.05);但地特胰岛素联合瑞格列奈组的胰岛素用量、低血糖发生率均低于诺和灵30R组(P<0.05)。结论地特胰岛素与联合瑞格列奈治疗方案对于新诊断T2DM患者安全、有效、方便,低血糖发生率小,地特胰岛素可改善胰岛功能。
Seventy-eight patients with newly diagnosed T2DM were randomly assigned to insulin detrostor plus repaglinide and pre-mixed insulin (noradren 30R) for treatment. FBG, 2hBG, HbA1c, CP, BMI, The incidence of blood sugar, insulin dosage. Results After treatment, FBG, 2hBG and HbA1c in both groups were significantly lower than those in baseline (P <0.05), but there was no significant difference between the two groups (P> 0.05). However, the combination of insulin detemir and repaglinide Dosage and incidence of hypoglycemia were lower than those of Norvuling 30R group (P <0.05). Conclusion The combination of detemir insulin and repaglinide is safe, effective and convenient for patients with newly diagnosed T2DM. The incidence of hypoglycemia is small, and insulin detemir can improve the function of islets.